Effectiveness and safety of monoclonal antibodies against amyloid-beta vis-a-vis placebo in mild or moderate Alzheimer's disease.

ABSTRACT:

Backgrounds and objectives

Currently, no consensus has been reached on the therapeutic implications of monoclonal antibodies against amyloid-beta (Aβ) in Alzheimer's disease (AD). This study aimed to examine the effectiveness and safety of monoclonal antibodies against Aβ as a whole and also to determine the superiority of individual antibodies vis-à-vis placebo in mild or moderate AD.

Methods

Literature retrieval, article selection, and data abstraction were performed independently and in duplicate. Cognition and function were appraised by the Mini-Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), Disability Assessment for Dementia (DAD), and Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB). Effect sizes are expr

SUBMITTER: Hao Y 

PROVIDER: S-EPMC10050585 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature